US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
Provider: View Press Release Type: Link Title: US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults | GSK Description: Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Provider: View Press Release Type: Link Title: GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion | GSK Description: Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease
European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
Provider: View Press Release Type: Link Title: European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer | GSK Description: Regulatory submission based on pivotal data from Part 1 of the RUBY phase III trial
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Provider: View Press Release Type: Link Title: GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health | GSK Description: Acquisition further strengthens specialty medicines and respiratory pipeline.
Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years
Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years
Provider: View Press Release Type: Link Title: Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years | GSK Description: Gepotidacin is a late-stage antibiotic in development in GSK’s growing infectious diseases portfolio
